BR112022026084A2 - Peptídeo, ácido nucleico, composição farmacêutica, uso in vitro de um peptídeo marcado, método in vitro para detectar uma desregulação da expressão de células receptoras de vasopressina-2 e uso de um peptídeo - Google Patents
Peptídeo, ácido nucleico, composição farmacêutica, uso in vitro de um peptídeo marcado, método in vitro para detectar uma desregulação da expressão de células receptoras de vasopressina-2 e uso de um peptídeoInfo
- Publication number
- BR112022026084A2 BR112022026084A2 BR112022026084A BR112022026084A BR112022026084A2 BR 112022026084 A2 BR112022026084 A2 BR 112022026084A2 BR 112022026084 A BR112022026084 A BR 112022026084A BR 112022026084 A BR112022026084 A BR 112022026084A BR 112022026084 A2 BR112022026084 A2 BR 112022026084A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- amino acid
- vitro
- deregulation
- vasopressin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
Abstract
PEPTÍDEO, ÁCIDO NUCLEICO, COMPOSIÇÃO FARMACÊUTICA, USO IN VITRO DE UM PEPTÍDEO MARCADO, MÉTODO IN VITRO PARA DETECTAR UMA DESREGULAÇÃO DA EXPRESSÃO DE CÉLULAS RECEPTORAS DE VASOPRESSINA-2 E USO DE UM PEPTÍDEO A presente divulgação se refere a um peptídeo compreendendo uma sequência tendo 80% ou mais de identidade de aminoácidos com a sequência de aminoácidos de SEQ ID NO. 1 abaixo: RPSX1CNLPVKPGPCX2GFFSAFYYSQKX3NKCHSFTYGGCAGNANRFST X4EKCRRTCX5X6 em que - X1 significa o resíduo de aminoácido F ou G, - X2 significa qualquer resíduo de aminoácido, exceto um resíduo de aminoácido básico, - X3 significa o resíduo de aminoácido T ou D, - X4 significa o resíduo de aminoácido I, L ou E, - (i) X5 significa V e X6 significa G ou (ii) X5 significa G e X6 significa V, e - o aminoácido localizado na posição 39 é A. A divulgação também se relaciona a vários usos diagnósticos e terapêuticos dos mesmos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20305696.5A EP3929209A1 (en) | 2020-06-24 | 2020-06-24 | Vasopressin-2 receptor antagonist peptides and uses thereof |
PCT/EP2021/067248 WO2021260068A1 (en) | 2020-06-24 | 2021-06-23 | Vasopressin-2 receptor antagonist peptides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022026084A2 true BR112022026084A2 (pt) | 2023-01-17 |
Family
ID=71614809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022026084A BR112022026084A2 (pt) | 2020-06-24 | 2021-06-23 | Peptídeo, ácido nucleico, composição farmacêutica, uso in vitro de um peptídeo marcado, método in vitro para detectar uma desregulação da expressão de células receptoras de vasopressina-2 e uso de um peptídeo |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230234994A1 (pt) |
EP (2) | EP3929209A1 (pt) |
JP (1) | JP2023533222A (pt) |
CN (1) | CN116322738A (pt) |
AU (1) | AU2021295295A1 (pt) |
BR (1) | BR112022026084A2 (pt) |
CA (1) | CA3182365A1 (pt) |
WO (1) | WO2021260068A1 (pt) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2854467A1 (en) * | 2011-11-11 | 2013-05-16 | Woomera Therapeutics | Antagonists for abnormal vasopressin v2 receptor and uses thereof |
EP2708235A1 (en) * | 2012-09-17 | 2014-03-19 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Peptide antagonists of the vasopressin-2 receptor |
-
2020
- 2020-06-24 EP EP20305696.5A patent/EP3929209A1/en not_active Withdrawn
-
2021
- 2021-06-23 CN CN202180052406.2A patent/CN116322738A/zh active Pending
- 2021-06-23 AU AU2021295295A patent/AU2021295295A1/en active Pending
- 2021-06-23 US US18/002,625 patent/US20230234994A1/en active Pending
- 2021-06-23 WO PCT/EP2021/067248 patent/WO2021260068A1/en unknown
- 2021-06-23 EP EP21733839.1A patent/EP4171607A1/en active Pending
- 2021-06-23 JP JP2022580195A patent/JP2023533222A/ja active Pending
- 2021-06-23 CA CA3182365A patent/CA3182365A1/en active Pending
- 2021-06-23 BR BR112022026084A patent/BR112022026084A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
EP3929209A1 (en) | 2021-12-29 |
WO2021260068A1 (en) | 2021-12-30 |
CN116322738A (zh) | 2023-06-23 |
US20230234994A1 (en) | 2023-07-27 |
CA3182365A1 (en) | 2021-12-30 |
AU2021295295A1 (en) | 2023-02-02 |
EP4171607A1 (en) | 2023-05-03 |
JP2023533222A (ja) | 2023-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wolfenden et al. | Water, protein folding, and the genetic code | |
Reubi | Evidence for two somatostatin-14 receptor types in rat brain cortex | |
Ito et al. | Activation of calcium signaling through Trpv1 by nNOS and peroxynitrite as a key trigger of skeletal muscle hypertrophy | |
Perez-Polo et al. | Steroid induction of nerve growth factor synthesis in cell culture | |
ES2552020T3 (es) | Péptido derivado de WNT10 y su uso | |
McBean et al. | Molecular mechanisms of cystine transport | |
EP1181313B1 (de) | Peptide zur vakzinierung gegen das humane cmv | |
Ahluwalia et al. | Aging impairs transcriptional regulation of vascular endothelial growth factor in human microvascular endothelial cells: implications for angiogenesis and cell survival. | |
BR112022009707A2 (pt) | Receptores de tcr prame e usos dos mesmos | |
Gallorini et al. | Hyaluronic acid increases tendon derived cell viability and proliferation in vitro: comparative study of two different hyaluronic acid preparations by molecular weight | |
Chiu et al. | Adrenomedullin regulates sperm motility and oviductal ciliary beat via cyclic adenosine 5′-monophosphate/protein kinase A and nitric oxide | |
Zhang et al. | Bm-TFF2, a toad trefoil factor, promotes cell migration, survival and wound healing | |
GOLDRING et al. | Parathyroid hormone inhibitors: comparison of biological activity in bone-and skin-derived tissue | |
Zhang et al. | Cytotoxic activity and probable apoptotic effect of Sph2, a sphigomyelinase hemolysin from Leptospira interrogans strain Lai | |
BR112022026084A2 (pt) | Peptídeo, ácido nucleico, composição farmacêutica, uso in vitro de um peptídeo marcado, método in vitro para detectar uma desregulação da expressão de células receptoras de vasopressina-2 e uso de um peptídeo | |
Zhang et al. | The expression of CAP1 after traumatic brain injury and its role in astrocyte proliferation | |
Koyama et al. | Endothelins are extracellular signals modulating cytoskeletal actin organization in rat cultured astrocytes | |
McFarland et al. | The role of myostatin in chicken (Gallus domesticus) myogenic satellite cell proliferation and differentiation | |
Tsai et al. | Inhibitory action of L-type Ca2+ current by paeoniflorin, a major constituent of peony root, in NG108-15 neuronal cells | |
Zhu et al. | Structure-function relationships of insulin receptor interactions in cultured mouse astrocytes | |
Proulx et al. | Integrin α5 expression by the ARPE-19 cell line: comparison with primary RPE cultures and effect of growth medium on the α5 gene promoter strength | |
ES2543198T3 (es) | Mutantes de FSH | |
EP2808342B1 (en) | Medium for in-vitro toxicity testing and in-vitro toxicity test method using the same | |
Ching et al. | Characterization of two populations of statin and the relationship of their syntheses to the state of cell proliferation. | |
Cardoso et al. | New and cost effective cell-based assay for Dialyzed Leukocyte Extract (DLE)-induced Jurkat cells proliferation under azathioprine treatment |